MAS Alzheimerhilfe

The use of implantable cardioverter defibrillators (ICD) has been shown to improve survival in patients at risk of sudden cardiac death; however, due to the continuous risk of sudden loss of consciousness during arrhythmia or ICD intervention, they pose apotential risk to other road users while driving. Alarge number of opinions and recommendations from authorities and medical societies all over the world exist regarding driving restrictions after ICD implantation. This analysis provides an overview of the recommendations on driving restrictions from several countries. Furthermore, the use of the wearable and the subcutaneous ICD are taken into account.

Do we have to change therapeutic considerations in peripheral arterial disease?Robert Berent and Helmut SinzingerRobert BerentHerzReha Bad Ischl, Center for Cardiovascular Rehabilitation, Bad Ischl, AustriaSearch for more papers by this author and Helmut SinzingerInstitute for Diagnosis and Treatment of Lipid Disorders and Atherosclerosis, Vienna, AustriaSearch for more papers by this authorPublished Online:December 28, 2017https://doi.org/10.1024/0301-1526/a000673PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit SectionsMoreLiteratureFowkes FG, Murray GD & Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208. First citation in articleCrossref Medline, Google ScholarHankey GJ, Norman PE & Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295(5):547–53. First citation in articleCrossref Medline, Google ScholarCAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39. First citation in articleCrossref Medline, Google ScholarBhatt DL, Fox KA & Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17. First citation in articleCrossref Medline, Google ScholarBhatt DL, Flather MD & Hacke W, et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982–8. First citation in articleCrossref Medline, Google ScholarHiatt WR, Fowkes FG & Heizer G, et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017;376(1):32–40. First citation in articleCrossref Medline, Google ScholarBonaca MP, Bhatt DL & Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719–28. First citation in articleCrossref Medline, Google ScholarLi X, Zhou G & Zhou X, et al. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci. 2013;332(1–2):92–6. First citation in articleCrossref Medline, Google ScholarMoon JY, Franchi F & Rollini F, et al. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. J Cardiovasc Pharmacol Ther. 2017 Jan 1:1074248417708617. doi: 10.1177/1074248417708617, epub ahead of print. First citation in articleGoogle ScholarAnand SS & Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 suppl S):62S–9S. First citation in articleCrossref Medline, Google ScholarAnand S, Yusuf S & Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27. First citation in articleCrossref Medline, Google ScholarPoterucha TJ & Goldhaber SZ. Warfarin and Vascular Calcification. Am J Med. 2016;129(6):635.e1–4. First citation in articleCrossref Medline, Google ScholarMega JL, Braunwald E & Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19. First citation in articleCrossref Medline, Google ScholarGibson CM, Mehran R & Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423–34. First citation in articleCrossref Medline, Google ScholarEikelboom JW, Connolly SJ & Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14):1319–30. doi: 10.1056/NEJMoa1709118. First citation in articleCrossref Medline, Google ScholarAzarbal A & Clavijo L, Gaglia MA Jr. Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? J Cardiovasc Pharmacol Ther. 2015;20(2):144–56. First citation in articleCrossref Medline, Google ScholarWhayne TF. A Review of the Role of Anticoagulation in the Treatment of Peripheral Arterial Disease. Int J Angiol. 2012;21:187–94. First citation in articleCrossref Medline, Google ScholarJones WS, Hellkamp AS & Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J. 2014;35(4):242–9. First citation in articleCrossref Medline, Google ScholarHu PT, Lopes RD & Stevens SR, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17; 6(1). pii: e004699. doi: 10.1161/JAHA.116.004699. First citation in articleMedline, Google ScholarFiguresReferencesRelatedDetailsCited byAntithrombotic treatment in peripheral artery diseaseDan-Mircea Olinic, Dan Alexandru Tataru, Calin Homorodean, Mihail Spinu, and Maria Olinic21 November 2017 | Vasa, Vol. 47, No. 2 Volume 47Issue 1January 2018ISSN: 0301-1526eISSN: 1664-2872 Published onlineDecember 28, 2017 InformationVasa (2018), 47, pp. 5-6 https://doi.org/10.1024/0301-1526/a000673.© 2018Hogrefe AGPDF download

Treatment of lipid disorders (dyslipidemia) is the cornerstone of atherosclerosis prevention and reduction of progression. Lifestyle modification is the first step to improve the plasma lipid profile. Statins play a central role in the reduction of LDL cholesterol. Whether and to what extent other lipids such as triglycerides or lipoprotein(a) should also be treated depends on the extent of atherosclerotic disease and its progression over time. Especially in residential cardiac rehabilitation we have the opportunity to encourage adherence and adapt medication as necessary due to a face to face contact over 4 weeks. Moreover, the prescription for a PCSK9-inhibitor could be resolved or the indication for a lipoprotein apheresis could be considered.

A 46-year-old lean man presented with rapidly progressing shortness of breath at rest, chest discomfort, lower limb oedema, and general fatigue over the past 3 weeks. Medical history included hearing loss, proteinuria due to focal segmental glomerular sclerosis and visual impairment due to changes in the retinal pigment epithelium and macular dystrophy ( Panels A–C ). The patient had impaired glucose tolerance. Family history showed diabetes and deafness in maternal relatives. On admission, blood pressure was 100/60 mmHg, heart rate was 118 beats …